

# VI EULAR Scientifically Endorsed Course on Systemic Lupus Erythematosus

Pisa, September 1-6, 2013

## *Preliminary Programme*

### ***Sunday, September 1<sup>st</sup>***

17.00 – 18.00

Arrival and registration of participants

#### *Course presentation*

18.00 – 18.30 *S. Bombardieri*

Course presentation

18.30 – 19.00 *F. Fontes*

Is it possible to screen SLE patients for neuropsychiatric involvement?

### ***Monday, September 2<sup>nd</sup>***

#### ***Morning***

##### *Pathogenesis of SLE*

09.00 – 09.30 *M. Galeazzi*

The genetics of SLE

09.30 – 10.00 *M. Cutolo*

Hormones and vitamin D in the pathogenesis of SLE

10.00 – 10.30 *P. Migliorini*

Pathogenetic antibodies in SLE humoral immunity and SLE

#### ***10.30 – 11.00 Coffee break***

11.00 – 11.30 *R. Voll*

Cellular immunity in SLE

11.30 – 12.00 *A. Doria*

An overview of the pathogenesis of SLE: specific organ involvement and potential therapeutic targets

#### ***Afternoon***

##### *Highlights on SLE treatment*

14.30 – 15.00 *J.W.J Bijlsma*

Corticosteroids: principles of therapy and monitoring

15.00 – 15.30 *G. Ruiz Irastorza*

“Traditional drugs” in SLE. Focus on immunosuppressive drugs

15.30 – 16.00 *M. Mosca*

New treatments in SLE in clinical practice: when to start and when to stop

16.00 – 17.00 *Clinical exercise*

A core set chart to collect clinical data in routine clinical practice

### ***Tuesday, September 3<sup>rd</sup>***

#### ***Morning***

##### *CNS and skin involvement*

09.00 – 09.30 *P. Meroni*

Pathogenesis of CNS involvement in SLE

09.30 – 10.00 *M. Govoni* The clinical picture of neuropsychiatric lupus  
10.00 – 10.30 *G. Bertias* EULAR recommendations for NPSLE: pitfalls and challenges

**10.30 – 11.00 Coffee break**

11.00 – 11.30 *A. Khun* Overview and treatment of cutaneous manifestations in lupus erythematosus

11.30 – 12.30 *Clinical exercise*

12.30 – 13.00 *Q&A on clinical cases*

**Afternoon**

*Kidney involvement*

14.30 – 15.00 *G. Moroni* Clinical and laboratory features of LN and prognostic factors

15.00 – 15.30 *F. Houssiau* Treatment of LN: old and new approaches

15.30 – 16.00 *D.T. Boumpas* EULAR Recommendations for the management of lupus nephritis

16.00 – 16.30 *J. Berden* Endstage renal disease: prevalence and management

16.30 – 17.30 *Q&A on clinical cases*

**Wednesday, September 4<sup>th</sup>**

**Morning**

*Family planning, assisted fertility, pregnancy, delivery, menopause and women health in SLE*

09.00 – 09.30 *A. Tincani* Contraception, prevention of infertility and hormonal therapies in SLE

09.30 – 10.00 *M. Ostensen* Drug therapy and toxicity in pregnancy and lactation

10.00 – 10.30 *F. Strigini* Outcome of pregnancy in patients with SLE

**10.30 – 11.00 Coffee break**

11.00 – 11.30 *M.A. Khamashta* Therapeutic algorithms for active SLE in pregnancy

11.30 – 12.00 *A. Brucato* Neonatal lupus and outcome of babies of SLE patients

12.00 – 13.00 *Q&A on clinical cases*

**Afternoon: FREE**

**Thursday, September 5<sup>th</sup>**

**Morning**

*Assessment of SLE in clinical trials and routine clinical practice*

09.00 09.30 *M. Aringer* The SLICC classification and diagnostic criteria for SLE

09.30 – 10.00 *I. Bruce* Assessment of disease activity and damage and outcomes in clinical trials in SLE  
10.00 – 10.30 *M. Jolly* Patient reported outcomes in SLE

**10.30 – 11.00 Coffee break**

11.00 – 11.30 *R.F. van Vollenhoven* Treat to target in SLE  
11.30 – 12.00 *M. Schneider* Pitfalls of trials in SLE  
12.00 – 12.30 *N. Costedoat-Chalumeau* Hydroxychloroquine and SLE: what's new

**Afternoon**

14.30 – 15.00 *J. Yazdany* Quality of care in SLE  
15.00 – 15.30 *R. Cervera* SLE and anti-phospholipid syndrome  
15.30 – 16.00 *A.G. Tzioufas* SLE and Sjögren's syndrome: an overlap syndrome with a specific clinical profile?  
16.00 - 16.30 *C. Tani* Rhuus syndrome  
16.30 – 17.30 *Q&A on clinical cases*

**Friday, September 6<sup>th</sup>**

**Morning**

*Can we further improve SLE prognosis?*

09.00 – 09.30 *C. Vasconcelos* Causes of death and SLE  
09.30 – 10.00 *R. Gerli* Atherosclerosis and SLE  
10.00 – 10.30 *Y. Shoenfeld* SLE and APS induced by vaccines

**10.30 – 11.00 Coffee break**

*Final lecture*

11.00 – 11.30 *S. Bombardieri* Can we further improve SLE prognosis?  
11.30 – 12.00 Course conclusions  
CME credits and departure of participants